MiMedx MDXG 深 沪
已收盘 10-09 16:00:00 美东时间
4.67
+0.050
+1.08%
华盛通- 最 高4.695
- 今 开4.58
- 成交量 39.11万股
- 最 低 4.58
- 昨 收 4.62
- 总市值 68.15万
- 52周最高 7.97
- 市盈率 静 14.40
- 换手率 0.27%
- 52周最低 3.025
- 委 比 33.34%
- 总股本 0.00亿
- 历史最高 18.25
- 量 比 0.38
- 振 幅 2.49%
- 历史最低 0.83
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILL
MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation challenging the U.S. Food and Drug Administration’s ("FDA") regulatory classification of AXIOFILL, the...
09-24 04:03
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
U.S. District Court overturns FDA's classification of MIMEDX's AXIOFILL, ruling it should be considered a Section 361 HCT/P, not a biological product. Court found FDA's minimal-manipulation analysis flawed, as it failed to consider tissue characteristics relevant to recipient use. FDA must reconsider classification. MIMEDX expresses satisfaction with the ruling, noting AXIOFILL's safety and effectiveness since its 2022 launch.
09-23 20:01
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
Craig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8
Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and raises the price target from $6 to $8.
08-28 02:40
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target
Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.
08-17 19:58
MiMedx Earnings Call: Surgical Strength, Wound Strain
MiMedx Group Inc. (($MDXG)) has held its Q2 earnings call. Read on for the main...
08-02 08:25
Meta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday. Shares of Meta Platforms Inc (NASDAQ:META) fell sharply in pre-market trading after the company posted mixed financial results for the second quarter. Meta reported second-quarter revenue of $60.80 bil...
07-30 20:03
MiMedx Group to Acquire Sanara MedTech in Merger
The latest announcement is out from MiMedx Group ( ($MDXG) ). On July 29, 2026,...
07-30 04:41
MiMedx Group shares are trading lower. The company reported Q2 financial results.
MiMedx Group shares are trading lower. The company reported Q2 financial results.
07-30 04:41
